Thermo Fisher Q2 2026 Revenue Beats Estimates, Up 10.5%
Thermo Fisher (TMO) reported Q2 2026 results beating market revenue expectations, with sales up 10.5% year over year to $11.99 billion. Non-GAAP EPS of $6.03 was 5.6% above consensus estimates.
Key Numbers
Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.
Key Financial Results
| Metric | Q2 2026 | YoY Change |
|---|---|---|
| Revenue | $11.99B | +10.5% |
| Non-GAAP EPS | $6.03 | +5.6% vs. estimates |
| Adjusted EPS | $6.03 | N/A |
Highlights from the Release
The company attributed the strong performance to broad-based end market growth and strategic portfolio moves. No further details on specific segments were provided.
Guidance
Thermo Fisher did not issue formal guidance for the next quarter or full year 2026 in this release.
Impact on Stock
While the stock reaction was not explicitly mentioned, beating expectations typically leads to positive trading sessions.
What This Means for Investors
Thermo Fisher's results reflect sustained demand for life sciences products and services, reinforcing its market position. Investors should monitor future guidance to assess growth sustainability.
Frequently Asked Questions
Found this useful? Share it